| Literature DB >> 34236786 |
Ozge Ozcan Abacioglu1, Nermin Yildiz Koyunsever1, Salih Kilic1, Arafat Yildirim1, Ibrahim Halil Kurt1.
Abstract
INTRODUCTION: The Glasgow prognostic score (GPS) reflects host systemic inflammatory response and has been reported to be significant as a prognostic indicator in cancer-bearing patients. The aim of this study was to evaluate the predictive value of GPS in outcomes of patients with severe aortic stenosis who were treated with transcatheter aortic valve implantation (TAVI).Entities:
Keywords: Aortic Valve Stenosis; C-Reactive Protein; Hospital Mortality; Prognosis; Serum Albumin; Transcatheter Aortic Valve Replacement
Mesh:
Substances:
Year: 2021 PMID: 34236786 PMCID: PMC8641765 DOI: 10.21470/1678-9741-2020-0269
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Association of GPS with patients' characteristics.
| GPS=0 (n=28) | GPS=1 (n=40) | GPS=2 (n=11) | ||
|---|---|---|---|---|
| Age (years) | 76.3±8.9 | 81.5±7.1 | 80.7±4.7 | 0.026 |
| Male (n, %) | 8 (28.5) | 14 (35) | 7 (63.6) | 0.118 |
| Comorbidity (n, %) | ||||
| HT | 3 (10.7%) | 11 (27.5%) | 2 (18.1 %) | 0.212 |
| DM | 3 (10.7%) | 7 (17.5%) | 3 (27.2%) | 0.438 |
| CAD | 15 (53.5%) | 18 (45%) | 8 (72.7%) | 0.294 |
| HPL | 10 (36) | 16 (40) | 4 (36) | 0.574 |
| Laboratory findings | ||||
| Hb (g/dL) | 11.8±1.8 | 11.4±1.6 | 10.7±0.9 | 0.158 |
| Glucose (mg/dL) | 128.4±67.6 | 121.3±43.7 | 129.5±36.2 | 0.828 |
| Creatinine (mg/dL) | 1.0±1.2 | 1.0±0.5 | 1.0±0.2 | 0.971 |
| Urea (mg/dL) | 45.6±27.5 | 53.0±25.2 | 62.3±26.7 | 0.191 |
| ALT (U/L) | 15.6±7.8 | 14.4±5.6 | 14.9±5.9 | 0.764 |
| AST(U/L) | 24.2±8.2 | 25.0±8.2 | 21.3±11.8 | 0.475 |
| LDL (mg/dL) | 122.8±35.4 | 119.4±39.7 | 107.3±19.7 | 0.515 |
| pro-BNP (pg/mL) | 3793.9±4734.3 | 6353.3±10240.0 | 5011.1±6869.2 | 0.565 |
| GFR (ml/m) | 78.7±18.0 | 66.6±23.8 | 52.5±13.4 | 0.024 |
| Echocardiography | ||||
| EF (%) | 51.4±9.9 | 52.0±8.8 | 55.5±9.1 | 0.515 |
| Preoperative mean gradient (mmHg) | 49.6±13.2 | 49.2±8.4 | 50.7±12.0 | 0.935 |
| EuroSCORE II | 4.89±2.75 | 4.66±2.87 | 7.18±5.75 | 0.500 |
ALT=alanine transaminase; AST=aspartate transaminase; CAD=coronary artery disease; DM=diabetes mellitus; EF=ejection fraction; EuroSCORE=European System for Cardiac Operative Risk Evaluation; GFR=glomerular filtration rate; GPS=Glasgow prognostic score; Hb=hemoglobin; HPL=hyperlipidemia; HT=hypertension; LDL=low-density lipoprotein; pro-BNP=pro-brain type natriuretic peptide
Statistically significant
Fig. 1Percent of cases which reached endpoints according to the Glasgow prognostic score (GPS). A) GPS 0; B) GPS 1; C) GPS 2.
Characteristics and echocardiographic and laboratory findings of patients according to primary endpoints.
| Alive (n= 64) | Reach endpoints (n=15) | ||
|---|---|---|---|
| Age, years | 79.5±8.2 | 79.8±6.3 | 0.130 |
| Gender (male, %) | 20 (69) | 9 (31) | 0.038 |
| HT (n, %) | 13 (20.3) | 3 (20) | 0.956 |
| DM (n, %) | 9 (14) | 4 (26.6) | 0.248 |
| CAD (n, %) | 33 (51.5) | 8 (53.3) | 0.747 |
| EF (%) | 52.2±9.2 | 52.6±9.0 | 0.431 |
| Preoperative gradient (mmHg) | 49.4±10.8 | 50.1±9.9 | 0.095 |
| Albumin (mg/dL) | 36.3±3.2 | 33.0±4.8 | 0.219 |
| CRP (mg/L) | 8.2±12.8 | 8.0±7.1 | 0.396 |
| Urea (mg/dL) | 53.0±28.2 | 46.0±16.8 | 0.492 |
| Creatinine (mg/dL) | 0.8±0.5 | 0.9±0.3 | 0.472 |
| Hb (g/dL) | 11.5±1.7 | 10.9±1.0 | 0.973 |
| Glucose (mg/dL) | 125.0±53.3 | 124.6±46.3 | 0.332 |
| AST (U/L) | 24.1±8.4 | 24.7±10.3 | 0.297 |
| ALT (U/L) | 15.1±6.9 | 14.1±4.0 | 0.565 |
| LDL (mg/ dL) | 118.3±35.5 | 122.3±39.7 | 0.392 |
| Pro-BNP (pg/mL) | 4572.0±7213.5 | 8648.5±11829.3 | 0.435 |
| GFR (ml/m) | 68.7±22.0 | 63.8±24.0 | 0.368 |
ALT=alanine transaminase; AST=aspartate transaminase; CAD=coronary artery disease; CRP=C-reactive protein; DM=diabetes mellitus; EF=ejection fraction; GFR=glomerular filtration rate; Hb=hemoglobin; HT=hypertension; LDL=low-density lipoprotein; pro-BNP=pro-brain type natriuretic peptide
Univariate and multivariate analysis of prognostic factors associated with primary endpoints in patients who underwent TAVI.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 0.882 | 0.747-1.042 | 0.140 | 0.976 | 0.898-1.060 | 0.558 |
| Gender | 0.897 | 0.060-13.388 | 0.937 | - | - | - |
| EF | 0.918 | 0.770-1.095 | 0.341 | - | - | - |
| Preoperative gradient | 0.975 | 0.841-1.131 | 0.741 | - | - | - |
| pro-BNP | 1.000 | 1.000-1.000 | 0.584 | - | - | - |
| GPS | 11.789 | 0.940-147.837 | 0.056 | 4.383 | 1.636-11.739 | 0.003 |
CI=confidence interval; EF=ejection fraction; GPS=Glasgow prognostic score; OR=odds ratio; pro-BNP=pro-brain type natriuretic peptide; TAVI=transcatheter aortic valve implantation
Statistically significant
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
|
|
|
|
| |
| Authors' roles & responsibilities | |
|---|---|
| OOA | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| NYK | Substantial contributions to the conception or design of the work; final approval of the version to be published |
| SK | Drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| AY | Final approval of the version to be published |
| IHK | Final approval of the version to be published |